A5041312764- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- RNA modifications and cancer
- SARS-CoV-2 detection and testing
- Adenosine and Purinergic Signaling
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- COVID-19 diagnosis using AI
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory Support and Mechanisms
- Radiomics and Machine Learning in Medical Imaging
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Autophagy in Disease and Therapy
- Immune Cell Function and Interaction
- Medical Imaging and Pathology Studies
- Calcium signaling and nucleotide metabolism
- Immunotherapy and Immune Responses
- Genetic factors in colorectal cancer
- Pleural and Pulmonary Diseases
- Infectious Disease Case Reports and Treatments
- Sarcoidosis and Beryllium Toxicity Research
- Congenital Diaphragmatic Hernia Studies
Centre Hospitalier Universitaire de Nice
2017-2025
Hôpital Pasteur
2019-2025
Université Côte d'Azur
2017-2025
Centre National de la Recherche Scientifique
2018-2024
Observatoire de la Côte d’Azur
2020-2024
Centre Antoine Lacassagne
2020-2024
Inserm
2018-2024
Institut de Recherche sur le Cancer et le Vieillissement de Nice
2017-2024
Institut de Biologie Valrose
2020-2021
Bases, Corpus, Langage
2021
Background Reliable predictive and prognostic markers are still lacking for patients treated with programmed death receptor 1 (PD1) inhibitors non-small cell lung cancer (NSCLC). The purpose of this study was to investigate the values different baseline metabolic parameters, including tumor volume (MTV), from 18F-fluorodeoxyglucose positron emission tomography–computed tomography ( 18 F-FDG PET/CT) scans in NSCLC PD1 inhibitors. Methods Maximum peak standardized uptake values, MTV total...
Only a subpopulation of non-small cell lung cancer (NSCLC) patients responds to immunotherapies, highlighting the urgent need develop therapeutic strategies improve patient outcome. We chemical positive modulator (HEI3090) purinergic P2RX7 receptor that potentiates αPD-1 treatment effectively control growth tumors in transplantable and oncogene-induced mouse models triggers long lasting antitumor immune responses. Mechanistically, molecule stimulates dendritic P2RX7-expressing cells generate...
Rationale: Diaphragm dysfunction is frequently observed in critically ill patients with difficult weaning from mechanical ventilation. Objectives: To evaluate the effects of temporary transvenous diaphragm neurostimulation on outcome and maximal inspiratory pressure. Methods: Multicenter, open-label, randomized, controlled study. Patients aged ⩾18 years invasive ventilation for ⩾4 days having failed at least two attempts received using a multielectrode stimulating central venous catheter...
The number of genomic alterations required for targeted therapy non-squamous non-small cell lung cancer (NS-NSCLC) patients has increased and become more complex these last few years. These molecular abnormalities lead to treatment that provides improvement in overall survival certain patients. However, treated tumors inexorably develop mechanisms resistance, some which can be with new therapies. characterization the needs performed a short turnaround time (TAT), as indicated by...
Background/Objectives: Immune checkpoint inhibitors (ICIs) benefit some lung cancer patients, but their efficacy is limited in advanced adenocarcinoma (LUAD) with EGFR mutations (EGFRm), largely due to a non-immunogenic tumour microenvironment (TME). Furthermore, EGFRm LUAD patients often experience increased toxicity ICIs. CD73, an ectonucleotidase involved adenosine production, promotes immune evasion and could represent novel therapeutic target. This study investigates CD73 expression...
Lung cancer (LC) is the leading cause of death from cancer. Early diagnosis LC paramount importance in terms prognosis. The health authorities most countries do not accept screening programmes based on low-dose chest CT (LDCT), especially Europe, because they are flawed by a high rate false-positive results, to large number invasive diagnostic procedures. These advocated further research, including companion biological tests that could enhance effectiveness screening. present project aims...
Tumor mutational burden (TMB) has emerged as an important potential biomarker for prediction of response to immune-checkpoint inhibitors (ICIs), notably in non-small cell lung cancer (NSCLC). However, its in-house assessment routine clinical practice is currently challenging and validation urgently needed. We have analyzed sixty NSCLC thirty-six melanoma patients with ICI treatment, using the FoundationOne test (FO) addition testing Oncomine TML (OTML) panel evaluated durable benefit (DCB),...
At a time when the world faces an emotional breakdown, crushing our dreams, if not, taking lives, we realize that together must fight war against COVID-19 outbreak even almost majority of scientific community finds itself confined at home. Every day, we, scientists, listen to latest news with its promises and announcements. Across world, surge clinical trials trying cure or slow down coronavirus pandemic has been launched bring hope instead fear despair. One first proposed trial drawn...
Efficient predictive biomarkers are urgently needed to identify non-small cell lung cancer (NSCLC) patients who could benefit from immune checkpoint blockade (ICB) therapy. Since chromatin remodeling is required for DNA repair process, we asked whether mutations in genes increase tumor mutational burden (TMB) and predict response ICB therapy NSCLC. Analysis of seven ICB-treated NSCLC cohorts revealed that three remodeling-related genes, including KMT2C, BCOR KDM5C, were significantly...
Background: Assessment of actionable EGFR mutations is mandatory for treatment-naïve advanced or metastatic non-squamous lung carcinoma (NSLC), but the results need to be obtained in less than 10 working days. For rapid testing, an EGFR-specific polymerase chain reaction (PCR) assay alternative and simple approach compared next generation sequencing (NGS). Here, we describe how a PCR can implemented single laboratory center (LPCE, Nice, France) as reflex testing NSLC. Methods: A total 901...
The introduction of liquid biopsies for the detection EGFR mutations in non-small cell lung cancer patients (NSCLC) has revolutionized clinical care. However, are technically challenging and require specifically trained personnel. To facilitate implementation from plasma, we have assessed a fully automated cartridge-based qPCR test that allows automatic directly plasma. We analyzed 54 NSCLC compared results cartridge-base device to an FDA-approved assay. Detection was comparable but slightly...
The histological distinction of lung neuroendocrine carcinoma, including small cell carcinoma (SCLC), large (LCNEC) and atypical carcinoid (AC), can be challenging in some cases, while bearing prognostic therapeutic significance. To assist pathologists with the differentiation histologic subtyping, we applied a deep learning classifier equipped convolutional neural network (CNN) to recognize neoplasms. Slides primary SCLC, LCNEC AC were obtained from Laboratory Clinical Experimental...